投稿信息
投稿信息
审稿速度
平均2月
（网友贡献，非官方数据）
投稿命中率
25.0%
（网友贡献，非官方数据）
审稿费用
暂无数据
版面费用
暂无数据
中国人发表比例
2023年中国人文章占该期刊总数量暂无数据 (2022年为100.00%)
自引率
2.5 %
年文章数
42
作者需知
暂无数据
NCBI查询
期刊简介
稿件收录要求
稿件收录要求
Published by Informa Pharmaceutical Science (formerly Ashley Publications).
ISSN: 1354-3784.
Expert Opinion on Investigational Drugs (EOID) is a monthly peer-reviewed journal, evaluating developments in pharmaceutical research, from animal studies through to the launch of a new medicine. Authors are encouraged to express their Expert Opinion of the status of the research under review, rather than simply reviewing the available data. Each issue of the journal also contains Editorials, Drug Evaluations, Clinical Trial Reports, Meeting Highlights and Paper Evaluations. The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D. Subscribers include most of the major pharmaceutical companies in the USA, Europe and Japan, and many biotechnology companies. Expert Opinion on Investigational Drugs adopts a systematic approach to coverage, with each issue focusing on one of the major therapeutic areas.
Expert Opinion on Investigational Drugs (EOID) is a monthly peer-reviewed journal, evaluating developments in pharmaceutical research, from animal studies through to the launch of a new medicine. Authors are encouraged to express their Expert Opinion of the status of the research under review, rather than simply reviewing the available data. Each issue of the journal also contains Editorials, Drug Evaluations, Clinical Trial Reports, Meeting Highlights and Paper Evaluations. The audience consists of scientists, managers and decision-makers in the pharmaceutical industry, and others closely involved in R&D. Subscribers include most of the major pharmaceutical companies in the USA, Europe and Japan, and many biotechnology companies. Expert Opinion on Investigational Drugs adopts a systematic approach to coverage, with each issue focusing on one of the major therapeutic areas.
